 |
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|
   |
| ONCX Reaches Another Crucial Milestone Begins Second Dosing in Phase 1 Clinical Trials |
|
 Hot Stock to Watch |
Company: Oncolix, Inc. (OTCQB: ONCX)
|
Last:
Price: 0.055
Change (%): + 0.0007 (1.29)
Volume: 196,250 |
 |
Oncolix Initiates Patient Recruitment of Second Cohort of Prolanta™ Phase 1 Trial in Advanced Ovarian Cancer
Dosing expected to begin in 1Q18
HOUSTON, Jan. 08, 2018 (GLOBE NEWSWIRE) - Oncolix, Inc., (OTCQB:ONCX) announced today that the Company’s clinical site investigator has initiated patient recruitment for the second dosing group for the Prolanta™ Phase 1 clinical trial in patients with advanced ovarian cancer. Patient dosing is anticipated to begin during the first quarter of 2018. The drug supply for this dosing group is scheduled to be shipped to the clinic from the contract manufacturer during January.
“Initiating patient recruitment of the second dosing group of our first Prolanta™ clinical trial is an important milestone for the company,” said Michael T. Redman, chief executive officer of Oncolix. “Recently, we have been focused on meeting our objectives to strengthen our public company infrastructure. Now we are moving forward with our primary objective and core value driver, which is to evaluate Prolanta™ in ovarian cancer patients with the ultimate goal of demonstrating its efficacy and safety and providing it as a breakthrough treatment option to patients. We look forward to begin dosing patients during the first quarter of 2018 and to complete dosing prior to the end of the year.”
Prolanta™ is being evaluated in an open-label dose escalation Phase 1 clinical trial in patients with advanced ovarian cancer. Patients are divided into three dosing groups, or cohorts. Each sequential cohort will evaluate a higher dose of Prolanta™. Patients will be evaluated over a 99-day period. Initial dosing for 28 days is followed by a two-week safety assessment period, and then continues for an additional 56 days if no toxicities are observed. The first cohort, treated with the lowest dose, was completed, and has shown no serious adverse events or dose-limiting toxicity. For more information about the Phase 1 clinical trial please visit: https://clinicaltrials.gov/ct2/show/NCT02534922?term=Prolanta&rank=1
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
